CLEVELAND & DALLAS--(BUSINESS WIRE)--Align Capital Partners’ (“ACP”) drug and alcohol testing solutions provider, Premier Biotech (“Premier” or the “Company”), announced the acquisitions of NexScreen and TransMed. These strategic acquisitions expand Premier’s global footprint and online presence, enhance the Company’s product portfolio and deepen customer relationships across healthcare, government and workplace markets.NexScreen provides point-of-care diagnostic testing solutions to customers a
Premier Biotech Broadens Product Portfolio With NexScreen and TransMed Acquisitions
